CDK4/6 Inhibition With Anti-PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD-1 Alone

被引：1
|
作者：
Bose, Sminu [1 ]
Lee, Tristan [2 ]
Choi, Shaelyn [1 ]
Fazlollahi, Ladan [3 ]
Rasiej, Michael J. [4 ]
Schwartz, Gary K. [1 ]
Ingham, Matthew [1 ]
机构：
[1] Columbia Univ, Irving Med Ctr, Dept Med, Div Hematol & Med Oncol, New York, NY USA
[2] Columbia Univ, Irving Med Ctr, Dept Med, New York, NY USA
[3] Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY USA
[4] Columbia Univ, Irving Med Ctr, Dept Radiol, New York, NY USA
来源：
JCO PRECISION ONCOLOGY | 2022年 / 6卷
关键词：
PEGYLATED-LIPOSOMAL DOXORUBICIN; PHASE-II; KINASE; VINCRISTINE; BLEOMYCIN; TRIAL; PD-L1; CDK6;
D O I：
10.1200/PO.21.00550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [41] ANTIGEN PRESENTATION PATHWAYS PRIME MELANOMA PATIENTS FOR MORE DURABLE RESPONSE TO ANTI-PD-1 CHECKPOINT BLOCKADE THERAPY
    Garg, Saurabh
    Welsh, Eric
    Fang, Bin
    Hernandez, Yuliana
    Rose, Trevor
    Gray, Jhanelle
    Koomen, John
    Berglund, Anders
    Mule, James
    Markowitz, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A139 - A140
  • [42] Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma
    Patrinely, James R., Jr.
    Baker, Laura X.
    Davis, Elizabeth J.
    Song, Haocan
    Ye, Fei
    Johnson, Douglas B.
    CANCER, 2020, 126 (15) : 3448 - 3455
  • [43] Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
    Starzer, Angelika M.
    Berghoff, Anna S.
    Hamacher, Rainer
    Tomasich, Erwin
    Feldmann, Katharina
    Hatziioannou, Teresa
    Traint, Stefan
    Lamm, Wolfgang
    Noebauer-Huhmann, Iris M.
    Furtner, Julia
    Muellauer, Leonhard
    Amann, Gabriele
    Bauer, Sebastian
    Schildhaus, Hans-Ulrich
    Preusser, Matthias
    Heller, Gerwin
    Brodowicz, Thomas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
  • [44] Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
    George, Suzanne
    Miao, Diana
    Demetri, George D.
    Adeegbe, Dennis
    Rodig, Scott J.
    Shukla, Sachet
    Lipschitz, Mikel
    Amin-Mansour, Ali
    Raut, Chandrajit P.
    Carter, Scott L.
    Hammerman, Peter
    Freeman, Gordon J.
    Wu, Catherine J.
    Ott, Patrick A.
    Wong, Kwok-Kin
    Van Allen, Eliezer M.
    IMMUNITY, 2017, 46 (02) : 197 - 204
  • [45] Anti-PD-1/L1 Priming Improves Response to MAPK Pathway Inhibition
    不详
    CANCER RESEARCH, 2021, 81 (20) : 5130 - 5130
  • [46] Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma
    Kif, Roberta
    Johansson, Junko
    Bagge, Roger Olofsson
    Martner, Anna
    EJSO, 2021, 47 (09): : 2460 - 2464
  • [47] Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
    Ascierto, Paolo A.
    Capone, Mariaelena
    Grimaldi, Antonio M.
    Mallardo, Domenico
    Simeone, Ester
    Madonna, Gabriele
    Roder, Heinrich
    Meyer, Krista
    Asmellash, Senait
    Oliveira, Carlos
    Roder, Joanna
    Grigorieva, Julia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [48] Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy
    Holmes, Zachary
    Courtney, Ashling
    Hiong, Alison
    BMJ CASE REPORTS, 2022, 15 (08)
  • [49] Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
    Klein, Oliver
    Kee, Damien
    Nagrial, Adnan
    Markman, Ben
    Underhill, Craig
    Michael, Michael
    Behren, Andreas
    Palmer, Jodie
    Tebbutt, Niall C. C.
    Carlino, Matteo S. S.
    Cebon, Jonathan
    CANCER, 2023, 129 (07) : 1129 - 1130
  • [50] Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.
    Mehmi, Inderjit
    Hill, Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345